Your browser is no longer supported. Please, upgrade your browser.
Settings
VKTX Viking Therapeutics, Inc. daily Stock Chart
VKTX [NASD]
Viking Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.45 Insider Own8.70% Shs Outstand74.65M Perf Week-6.65%
Market Cap671.10M Forward P/E- EPS next Y-0.50 Insider Trans-3.89% Shs Float63.68M Perf Month-22.03%
Income-20.90M PEG- EPS next Q-0.10 Inst Own61.80% Short Float35.48% Perf Quarter-15.03%
Sales- P/S- EPS this Y12.50% Inst Trans33.12% Short Ratio4.70 Perf Half Y-29.43%
Book/sh4.93 P/B1.82 EPS next Y-13.60% ROA-15.10% Target Price32.08 Perf Year137.20%
Cash/sh4.08 P/C2.21 EPS next 5Y40.00% ROE-15.80% 52W Range3.66 - 24.00 Perf YTD121.43%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.54% Beta2.89
Dividend %- Quick Ratio64.60 Sales past 5Y- Gross Margin- 52W Low145.63% ATR0.93
Employees4 Current Ratio64.60 Sales Q/Q- Oper. Margin- RSI (14)30.89 Volatility6.31% 8.44%
OptionableYes Debt/Eq0.00 EPS Q/Q51.50% Profit Margin- Rel Volume0.43 Prev Close9.31
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume4.81M Price8.99
Recom1.70 SMA20-16.94% SMA50-29.20% SMA200-8.04% Volume2,059,930 Change-3.44%
Dec-12-18Initiated B. Riley FBR Buy $16
Nov-19-18Upgrade Raymond James Outperform → Strong Buy
Sep-18-18Reiterated Raymond James Outperform $15 → $43
Sep-18-18Reiterated Maxim Group Buy $14 → $28
Sep-18-18Reiterated H.C. Wainwright Buy $15 → $28
Jul-20-18Initiated SunTrust Buy $14
Jun-28-18Initiated Raymond James Outperform
Jun-01-18Reiterated Laidlaw Buy $10 → $15
May-31-18Reiterated Maxim Group Buy $8 → $14
Mar-26-18Resumed H.C. Wainwright Buy $11
Nov-28-17Reiterated Maxim Group Buy $5 → $8
Nov-21-17Initiated ROTH Capital Buy
Nov-10-17Resumed H.C. Wainwright Buy $7
Jul-17-17Reiterated H.C. Wainwright Buy $5 → $7
Aug-11-16Reiterated Laidlaw Buy $20 → $10
May-24-16Initiated Maxim Group Buy $5
Apr-07-16Initiated H.C. Wainwright Buy $6
Dec-12-18 01:40AM  Hedge Funds Are Betting On Viking Therapeutics, Inc. (VKTX) Insider Monkey
Dec-10-18 10:28AM  Why Viking Therapeutics Stock Continued to Slide in November Motley Fool
Dec-08-18 03:03PM  Here's Why Madrigal Pharmaceuticals Fell 39.4% in November Motley Fool
Dec-03-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within The Trade Desk, United Rentals, ServiceMaster Global, Talend S.A, Viking Therapeutics, and SEACOR New Research Emphasizes Economic Growth GlobeNewswire
Nov-27-18 10:00AM  Growth Opportunities in Stocks Coming Off of Bottoms ACCESSWIRE -9.53%
Nov-19-18 02:57PM  Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade Benzinga
Nov-15-18 09:27PM  Edited Transcript of VKTX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-14-18 09:30AM  4 Healthcare Stocks To Watch On Wednesday ACCESSWIRE
08:31AM  Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc. Motley Fool
06:50AM  Todays Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals ACCESSWIRE
Nov-13-18 04:36PM  Stocks on the move: higher transportation and raw material cost clash with Home Depot's profitability Yahoo Finance Video
11:54AM  Viking Therapeutics Shows How Quickly This Market Can Turn TheStreet.com
11:00AM  VKTX: Phase 2 Data for VK2809 Presented at AASLD Zacks Small Cap Research
10:45AM  Why Viking Therapeutics Shares Are Finding Renewed Buying Interest Benzinga
09:15AM  4 Stocks To Watch As Healthcare Technology Industry Is Expecting Rapid Growth Through 2025 ACCESSWIRE
08:00AM  Why Viking Therapeutics Stock Is Bolting Higher Today Motley Fool
Nov-12-18 06:55PM  Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The Liver Meeting® 2018 PR Newswire
Nov-08-18 12:36PM  Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript Motley Fool -6.41%
Nov-07-18 04:05PM  Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
09:15AM  Why Viking Therapeutics Stock Sank in October Motley Fool
Oct-31-18 07:35AM  Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018 PR Newswire
Oct-27-18 07:00AM  Where Will Gilead Sciences, Inc. Be in 5 Years? Motley Fool
Oct-25-18 04:18PM  3 Top Stocks Under $20 Motley Fool +7.26%
Oct-24-18 09:25AM  Detailed Research: Economic Perspectives on Paychex, Coty, Bright Scholar Education, LendingClub, Energy Fuels, and Viking Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire -9.56%
Oct-23-18 10:54AM  CAT Stock Gets Thrown Into the Dumpster TheStreet.com
Oct-14-18 06:32AM  3 Top Small-Cap Stocks to Buy in October Motley Fool
Oct-11-18 02:21PM  Here's Why Viking Therapeutics Skyrocketed 33% in September Motley Fool
Oct-08-18 07:02AM  Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA) PR Newswire -5.39%
Oct-05-18 11:00AM  Liver Cancers Rising - Stocks to Watch ACCESSWIRE
Oct-04-18 08:51AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
07:02AM  Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018 PR Newswire
Oct-03-18 10:30AM  VKTX: Presentation of Full Data Set for VK5211 Phase 2 Trial Zacks Small Cap Research
Oct-02-18 06:02AM  3 Reasons Why Buying Viking Therapeutics on the Dip Could Pay Off Big Motley Fool -5.98%
Oct-01-18 08:29AM  Viking Therapeutics stock jumps 4.8% premarket on news of positive trial results MarketWatch -6.95%
08:00AM  Today's Research Reports on Trending Tickers: Viking Therapeutics and Amarin ACCESSWIRE
07:02AM  Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting PR Newswire
Sep-30-18 10:14AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-27-18 06:31AM  The Greatest Healthcare Stocks of the 21st Century -- and Some That Probably Will Be Motley Fool
Sep-26-18 03:21PM  5 Biotech Stocks to Play the Sectors Next Big Trend: NASH InvestorPlace
07:35AM  Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Sep-25-18 10:00AM  Forget Tilray, These 2 Biotech Stocks Have Far More Upside Motley Fool
Sep-24-18 01:00PM  VKTX: Positive Results for Phase 2 Study of VK2809 in NAFLD Zacks Small Cap Research +5.99%
Sep-22-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-20-18 08:06PM  Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock PR Newswire
09:02AM  The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut Benzinga
08:48AM  Is Viking Therapeutics the Best NASH Stock to Buy Now? Motley Fool
Sep-19-18 04:21PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
11:01AM  Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success Zacks
10:13AM  Viking Therapeutics Liver Candidate Passes Test, Shares Soar Zacks
08:47AM  The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Viking Therapeutics and Realm Therapeutics ACCESSWIRE
07:06AM  Viking Therapeutics stock rose 87% on results for its liver disease drug and the company has more in store this fall MarketWatch
Sep-18-18 05:04PM  What Happened in the Stock Market Today Motley Fool +87.30%
03:00PM  Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASH Motley Fool
11:55AM  Stocks Ignore Tariff News, And This Might Explain Why Investor's Business Daily
11:26AM  Viking Therapeutics Stock Skyrockets on Promising Fatty Liver Treatment Results InvestorPlace
10:00AM  Why Viking Therapeutics Stock Is Soaring Today Motley Fool
08:14AM  UPDATE: Viking Therapeutics stock rockets 140% after positive trial of non-alcoholic fatty liver treatment MarketWatch
07:21AM  Viking Therapeutics liver drug succeeds in mid-stage study Reuters
07:05AM  Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol PR Newswire
07:05AM  Viking Almost Triples After Fatty Liver Drug Meets Study Goals Bloomberg
Sep-11-18 06:30AM  3 Surging Biotech Stocks -- Can They Keep Climbing? Motley Fool
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List TheStreet.com
Sep-04-18 06:00AM  Why Viking Therapeutics Stock Gained 27% in August Motley Fool
Aug-30-18 01:38PM  A Lesson to Learn From Thursday's Market Action TheStreet.com +6.46%
Aug-29-18 06:00AM  Can Viking Therapeutics Stock Sail Even Higher? Motley Fool +5.23%
Aug-28-18 07:30AM  Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
Aug-24-18 08:00AM  Today's Research Reports on Stocks to Watch: Obalon Therapeutics and Viking Therapeutics ACCESSWIRE
Aug-19-18 09:02AM  Is Viking Therapeutics, Inc. a Buy? Motley Fool
Aug-15-18 04:43PM  3 Growth Stocks for in-the-Know Investors Motley Fool
Aug-13-18 09:45AM  VKTX: Data from P2 Trial of VK2809 in 4Q18 Zacks Small Cap Research
Aug-09-18 04:05PM  Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
02:30PM  Viking Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 07:30AM  Viking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018 PR Newswire
Jul-30-18 06:00AM  Analyst-Turned-CEO Says His Biotech Stock Is Cheap, Even After a 900% Rally Bloomberg -6.99%
Jul-25-18 07:45AM  Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks ACCESSWIRE
Jul-21-18 08:25AM  Should Biotech Investors Fear Dilution? Motley Fool
Jul-17-18 07:05AM  Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting PR Newswire -8.38%
Jul-14-18 07:16AM  3 Biotech Stocks With Big News Coming in NASH Motley Fool
Jul-13-18 07:31AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jul-08-18 09:30AM  3 Top Biotech Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jun-26-18 11:27AM  Viking Therapeutics, Buy the Dip? Motley Fool
07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-20-18 06:01AM  3 Small-Cap Biotech Stocks to Keep on Your Radar Motley Fool
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool +10.49%
09:40AM  3 Growth Stocks at Deep-Value Prices Motley Fool
08:10AM  Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jun-14-18 10:30AM  Are These Red-Hot NASH Stocks Still a Buy? Motley Fool
Jun-13-18 04:03PM  Here's Why Viking Therapeutics Rose as Much as 14.9% Today Motley Fool +9.09%
Jun-12-18 02:15PM  VKTX: Final Patient Enrolled in P2 Trial of VK2809; Raises Gross Proceeds of $77.6M in Public Offering Zacks Small Cap Research
07:05AM  Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
Jun-11-18 10:31AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool +8.59%
Jun-08-18 09:18AM  Now's the Time to Buy These 3 Stocks Motley Fool
Jun-07-18 08:30AM  Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock PR Newswire +6.39%
Jun-06-18 04:01PM  Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
08:15AM  Viking Therapeutics Recent VK2809 Update, Analyst Review and Target ACCESSWIRE
Jun-05-18 07:40AM  Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks ACCESSWIRE
07:01AM  Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease PR Newswire
Jun-02-18 04:10PM  Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal Benzinga
07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LIGAND PHARMACEUTICALS INC10% OwnerSep 25Sale19.15262,8815,034,2506,038,083Sep 27 09:25 PM
SINGLETON J MATTHEWDirectorMay 31Buy9.829,50093,2619,500May 31 07:04 PM
MORNEAU MICHAELVP, Finance and AdministrationMay 31Sale9.2521,551199,34794,035May 31 07:03 PM
Rowland Charles A JrDirectorMay 29Buy5.1630,000154,80030,000May 31 07:02 PM
Webster Stephen WDirectorMay 29Buy5.218,00041,7128,000May 31 06:59 PM
MACARTNEY LAWSONDirectorMay 29Buy5.2247,965250,32947,965May 31 06:57 PM